 |
|
|
|
|
| |
ViriLife Sexual Support Formula
HV6
|
|
|
|
IN STOCK - YES
|
What is ViriLife Sexual Support Formula?
ViriLife® Sexual Support Formula is a patented product created to naturally promote normal sexual function. ViriLife achieves the desired result by stimulating a release of nitric oxide, the signaling molecule that allows physical arousal to occur in both men and women.
ViriLife is the most powerful product of natural sexual potency formulas based on l-arginine. Patented for its unique formula & combination delivery mechanism, ViriLife contains OVER SEVEN TIMES the l-arginine of similar products. Additionally, it is more sophisticated with its use of theanine and ginseng to enhance the absorption of l-arginine.
Who Should Consider ViriLife Sexual Support Formula?
Though men's sexual difficulties are physically more apparent, women also suffer from the same root problem that afflicts men. Unfortunately, most attention in recent years has focused on addressing male erectile difficulties, leaving many women sexually frustrated. ViriLife increases nitric oxide levels and stimulating its release in women through the same biochemical mechanism as it does in men.
Related Articles
To be sure you never run out of your favorite products, we now offer our exclusive
Convenience Plan. This plan guarantees delivery of our
high quality products directly
to your door exactly when you need them. Additionally, you receive our lowest price on
each order. It is simple, convenient and free! And, you can change, add to, suspend or
cancel shipments at any time!
|
The 1998 Nobel Prize
The information that you are about to read concerning the action and function of nitric oxide made news when Robert F. Furchgott, Louis J. Ignarro and Ferid Murad, the scientists who made these breakthrough discoveries ("nitric oxide as a signalling molecule in the cardiovascular system"), won the 1998 Nobel Prize for Physiology or Medicine. It is this research that formed the basis for the development of ViriLife.
How an Erection is Achieved
In order for an erection to occur, a "pro-erection" chemical, Cyclic GMP, must be present in sufficient quantity to overcome an "anti-erection" enzyme (phosphodiesterase type-5, or "PDE-5") which breaks down Cyclic GMP. Furthermore, there must be sufficient quantities of nitric oxide available for the Cyclic GMP to act. When there is more Cyclic GMP in the penis than there is PDE-5, and nitric oxide is present in sufficient quantities, and given sufficient sexual arousal (which causes a local release of nitric oxide), an erection occurs. The reason for this is that Cyclic GMP is essentially a gate-keeper for blood entering the penis. When Cyclic GMP is present in high proportion to its antagonist enzyme, AND nitric oxide is present, the arteries to the penis dilate, the penis becomes engorged with blood and the force of turgor causes it to stiffen. Key to this system is the fact that when the arteries to the penis are open (dilated), the veins that draw blood away are pinched shut, otherwise blood would leave just as quickly as it enters and turgor would not build.
The Pharmaceutical Approach
The pharmaceutical solution to the chemical imbalance that prevents an erection is to block the action of the "bad" enzyme. Sildenafil citrate (the prescription drug) allows a chemical in the penis, called Cyclic GMP, to work unencumbered by its antagonist enzyme. The result is a relative increase in Cyclic GMP, and an erection is possible upon stimulation.
ViriLife - The Natural Approach
ViriLife achieve the desired result through a different route (although the same mechanism) by stimulating a release of nitric oxide. Using safe, natural substances, ViriLife stimulate a local release of nitric oxide in the corpus cavernosum. ViriLife contains a potent 1500mg of L-arginine per single serving, in addition to a unique support blend.
Most men who are considering pharmaceuticals as a solution to the problem of erectile dysfunction and who have taken the time to learn about the drug are aware of its possible (and unusual) side-effects. Headaches, visual distortions (blurred vision and blue halos), and blackouts in people who are also taking antihypertensive medicines are a few of the reported down sides. Pilots are banned from flying aircraft after taking the pharmaceutical. Most of us would prefer to take a natural product that lacked these side-effects.
The diagram below illustrates the function of this product:
While the pharmaceutical stabilizes Cyclic-GMP at their present levels, it does not increase these levels. ViriLife, however, increase Cyclic-GMP levels, and therefore, enhance sexual function, as opposed to simply producing an erection.
ViriLife is safe, natural, can be used by both men and women, allowing spontaneity, while actually increasing the sex drive and improving sexual health, and have no reported side effects.
ViriLife
Virilife is the latest release and most powerful product in this series of natural sexual potency formulas based on L-arginine. Patented for its unique formula & combination delivery mechanism (United States Patent No. 6,444,237), ViriLife contains OVER SEVEN TIMES the L-arginine of Veromax per serving. Additionally, it is far more sophisticated in its herbal combination using theanine and ginseng to enhance the absorption of L-arginine. Ginseng, specifically ginsenoside Rg1 and Rg3, is a nitric oxide ("NO") synthase catalyst which acts to enhance the production of NO significantly. Theanine, a fast acting vasodilator, allows all the ingredients to assimilate into the body at a much greater speed. Both mechanisms serve to cause the flooding action to overwhelm the arginase (the enzyme which breaks down arginine before it can release its NO).
Each of Virilife's ingredients contribute directly to more turgid erections/clitoral distensions since vascular insufficiency is a common mechanical deficit. In addition, Pygeum africanum provides relief from benign prostatic hyperplasia (swollen prostate), often a cause of or a contributor to, erectile dysfunction in itself.8,13
ViriLife Is Now Available as Tablets
Originally formulated as a highly absorbable (bio-available) mix-with-water drink for daily consumption, ViriLife is now available in tablets (blister-packed for freshness). Tablets are taken 2 per day.
Answers to our Most Frequently Asked ViriLife Questions
Recommended ViriLife Intake: One packet per day should be sufficient for most people. Allow 3 weeks of continuous use before deciding to increase to 2 packets per day (one in the morning, one in the evening).
Are these products right for me? This is a personal question, really. These products work as sexual enhancers to increases a person's sexual response by increasing the level of NO in your body. The degree of your "problem" will determine how much you need.
Is there a ViriLife formula for women?
Though men's sexual difficulties are physically more apparent, women also suffer from the same root problem that afflicts men. Unfortunately, most attention in recent years has focused on addressing male erectile difficulties, leaving many women sexually frustrated. ViriLife increases nitric oxide levels and stimulating its release in women through the same biochemical mechanism as it does in men.
Also Recommended:
Here are the two most common causes of erectile failure and their natural remedies:
- Atherosclerosis of the penile artery. It is strongly recommended that you have a thorough vascular examination.
- Alcohol, smoking and use of other drugs. Stop or diminish your use of these items and seek natural alternatives to certain prescription medicines.
What is of greatest concern, though, is the fact that since most erectile problems are due to atherosclerosis, many men are simply putting a "band-aid" on a much more serious problem--heart disease--and ignoring the root cause. ViriLife and pharmaceuticals address the problem at the site of the penis, not at the root of the problem. Unless you have been involved in a pelvic injury, had pelvic surgery, are a heavy smoker, chronic drinker, or are on a medication that inhibits the ability to have erections, there is a good chance that your problem is a symptom of heart disease!
Even if you choose to use pharmaceuticals (we understand how sensitive an issue the ability to have sexual intimacies with your partner is), please have a thorough vascular examination and take the appropriate steps to solve your problem at the root (See the recommendations above). Your partner will appreciate your having a healthy heart and vascular system much more than your having erections! Once you are in greater vascular health, odds are your erectile problem will subside.
|
|
|
Label Facts
 |
|
|
|
|
Supplement Facts
Serving Size: 2 Tablets
Servings per container: 30 |
|
| |
Amount Per Serving |
% Daily Value |
|
| L-Arginine |
1500 mg |
† |
|
| Proprietary Blend |
565 |
† |
|
| Hawthorn (Crataegus monogyna) berry 7:1 extract (4% vitexin flavonoids) |
|
|
|
Damiana (Tunera diffusa) 4:1 extract
|
|
|
|
| Suma (Pfaffia paniculata) root extract (2.5% beta-ecdysterone) |
|
|
|
| Ginkgo biloba extract (24% ginkgo flavone glycosides, 6% gingko terpene lactones) |
|
|
|
| Pygeum africanum extract (15% sterols) |
|
|
|
| L-Theanine |
|
|
|
| Ginseng (Panax ginseng) extract (80% ginsenosides) |
|
|
|
| Maca (Lepidium meyenii) root extract (0.6% glucosinolates) |
150 mg |
† |
|
| Long Jack (Eurycoma longifolia) root 4:1 extract |
25 mg |
† |
|
|
|
|
|
Other Ingredients: Dicalcium phosphate, cellulose (plant fiber), stearic acid (vegetable source).
|
|
|
|
Dietary Restrictions
 This is a vegetarian product.
|
References
- Adimoelja, A. (2000). "Phytochemicals and the breakthrough of traditional herbs in the management of sexual dysfunctions [In Process Citation]." Int J Androl 23(Suppl 2): 82-4.
- Ahumada, C., T. Saenz, D. Garcia, R. De La Puerta, A. Fernandez and E. Martinez (1997). "The effects of a triterpene fraction isolated from Crataegus monogyna Jacq. on different acute inflammation models in rats and mice. Leucocyte migration and phospholipase A2 inhibition." J Pharm Pharmacol 49(3): 329-31.
- Arletti, R., A. Benelli, E. Cavazzuti, G. Scarpetta and A. Bertolini (1999). "Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats." Psychopharmacology (Berl) 143(1): 15-9.
- Bahorun, T., B. Gressier, F. Trotin, C. Brunet, T. Dine, M. Luyckx, J. Vasseur, M. Cazin, J. C. Cazin and M. Pinkas (1996). "Oxygen species scavenging activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparations." Arzneimittelforschung 46(11): 1086-9.
- Bahorun, T., F. Trotin, J. Pommery, J. Vasseur and M. Pinkas (1994). "Antioxidant activities of Crataegus monogyna extracts." Planta Med 60(4): 323-8.
- Bayne, C. W., F. Donnelly, M. Ross and F. K. Habib (1999). "Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor- new evidence in a coculture model of BPH." Prostate 40(4): 232-41.
- Breu, W., M. Hagenlocher, K. Redl, G. Tittel, F. Stadler and H. Wagner (1992). "[Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism]." Arzneimittelforschung 42(4): 547-51.
- Carani, C., V. Salvioli, A. Scuteri, A. Borelli, A. Baldini, A. R. Granata and P. Marrama (1991). "[Urological and sexual evaluation of treatment of benign prostatic disease using Pygeum africanum at high doses]." Arch Ital Urol Nefrol Androl 63(3): 341-5.
- Carilla, E., M. Briley, F. Fauran, C. Sultan and C. Duvilliers (1984). "Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate." J Steroid Biochem 20(1): 521-3.
- Casarosa, C., M. Cosci di Coscio and M. Fratta (1988). "Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone." Clin Ther 10(5): 585-8.
- Casella, G. and A. Barbaro (1978). "[The role of mepartricin in the medical treatment of benign prostatic adenoma]." Arch Sci Med (Torino) 135(1): 95-8.
- Champault, G., J. C. Patel and A. M. Bonnard (1984). "A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia." Br J Clin Pharmacol 18(3): 461-2.
- Chatelain, C., W. Autet and F. Brackman (1999). "Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension." Urology 54(3): 473-8.
- Chen, M. W., R. M. Levin, P. Horan and R. B. Buttyan (1999). "Effects of Unilateral Ischemia on the Contractile Response of the Bladder: Protective Effect of Tadenan (Pygeum africanum Extract)." Mol Urol 3(1): 5-10.
- Chen, X. (1996). "Cardiovascular protection by ginsenosides and their nitric oxide releasing action." Clin Exp Pharmacol Physiol 23(8): 728-32.
- Chen, X. and T. J. Lee (1995). "Ginsenosides-induced nitric oxide-mediated relaxation of the rabbit corpus cavernosum." Br J Pharmacol 115(1): 15-8.
- Choi, Y. D., Z. C. Xin and H. K. Choi (1998). "Effect of Korean red ginseng on the rabbit corpus cavernosal smooth muscle." Int J Impot Res 10(1): 37-43.
- Choo, M. S., F. Bellamy and C. E. Constantinou (2000). "Functional evaluation of Tadenan on micturition and experimental prostate growth induced with exogenous dihydrotestosterone." Urology 55(2): 292-8.
- Clavert, A., C. Cranz, J. P. Riffaud, C. Marquer, J. Y. Lacolle and C. Bollack (1986). "[Effects of an extract of the bark of Pygeum africanum (V.1326) on prostatic secretions in the rat and in man]." Ann Urol 20(5): 341-3.
- Ernst, E. (1999). "Herbal medications for common ailments in the elderly." Drugs Aging 15(6): 423-8.
- Fan, Z. H., K. Isobe, K. Kiuchi and I. Nakashima (1995). "Enhancement of nitric oxide production from activated macrophages by a purified form of ginsenoside (Rg1)." Am J Chin Med 23(3-4): 279-87.
- Gillis, C. N. (1997). "Panax ginseng pharmacology: a nitric oxide link?" Biochem Pharmacol 54(1): 1-8.
- Glossmann, H., G. Petrischor and G. Bartsch (1999). "Molecular mechanisms of the effects of sildenafil (VIAGRA)." Exp Gerontol 34(3): 305-18.
- Goepel, M., U. Hecker, S. Krege, H. Rubben and M. C. Michel (1999). "Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro." Prostate 38(3): 208-15.
- Gomes, C. M., M. E. Disanto, P. Horan, R. M. Levin, A. J. Wein and S. Chacko (2000). "Improved contractility of obstructed bladders after Tadenan treatment is associated with reversal of altered myosin isoform expression." J Urol 163(6): 2008-13.
- Iehle, C., S. Delos, O. Guirou, R. Tate, J. P. Raynaud and P. M. Martin (1995). "Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors." J Steroid Biochem Mol Biol 54(5-6): 273-9.
- Jung, H. C., K. H. Mun, T. C. Park, Y. C. Lee, J. M. Park, K. Huh, D. H. Seong and J. K. Suh (1997). "Role of nitric oxide in penile erection." Yonsei Med J 38(5): 261-9.
- Kim, H., X. Chen and C. N. Gillis (1992). "Ginsenosides protect pulmonary vascular endothelium against free radical-induced injury." Biochem Biophys Res Commun 189(2): 670-6.
- Kim, H. J., D. S. Woo, G. Lee and J. J. Kim (1998). "The relaxation effects of ginseng saponin in rabbit corporal smooth muscle: is it a nitric oxide donor?" Br J Urol 82(5): 744-8.
- Kim, N. D., S. Y. Kang and V. B. Schini (1994). "Ginsenosides evoke endothelium-dependent vascular relaxation in rat aorta." Gen Pharmacol 25(6): 1071-7.
- Kondas, J., V. Philipp and G. Dioszeghy (1996). "Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia." Int Urol Nephrol 28(6): 767-72.
- Kondas, J., V. Philipp and G. Dioszeghy (1997). "[Sabal serrulata extract in the management of symptoms of prostatic hypertrophy]." Orv Hetil 138(7): 419-21.
- Krzeski, T., M. Kazon, A. Borkowski, A. Witeska and J. Kuczera (1993). "Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses." Clin Ther 15(6): 1011-20.
- Levin, R. M., S. S. Levin, Y. Zhao and R. Buttyan (1997). "Cellular and molecular aspects of bladder hypertrophy." Eur Urol 32(Suppl 1): 15-21.
- Mathe, G., M. Hallard, C. H. Bourut and E. Chenu (1995). "A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy." Biomed Pharmacother 49(7-8): 341-3.
- Moody, J. A., D. Vernet, S. Laidlaw, J. Rajfer and N. F. Gonzalez-Cadavid (1997). "Effects of long-term oral administration of L-arginine on the rat erectile response [see comments]." J Urol 158(3 Pt 1): 942-7.
- Palin, M. F., M. Faguy, J. G. LeHoux and G. Pelletier (1998). "Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity." Endocrine 9(1): 65-9.
- Paubert-Braquet, M., A. Cave, R. Hocquemiller, D. Delacroix, C. Dupont, N. Hedef and P. Borgeat (1994). "Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells." J Lipid Mediat Cell Signal 9(3): 285-90.
- Paubert-Braquet, M., J. M. Mencia Huerta, H. Cousse and P. Braquet (1997). "Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils." Prostaglandins Leukot Essent Fatty Acids 57(3): 299-304.
- Paubert-Braquet, M., F. O. Richardson, N. Servent-Saez, W. C. Gordon, M. C. Monge, N. G. Bazan, D. Authie and P. Braquet (1996). "Effect of Serenoa repens extract (Permixon) on estradiol/testosterone- induced experimental prostate enlargement in the rat." Pharmacol Res 34(3-4): 171-9.
- Rakotoarison, D. A., B. Gressier, F. Trotin, C. Brunet, T. Dine, M. Luyckx, J. Vasseur, M. Cazin, J. C. Cazin and M. Pinkas (1997). "Antioxidant activities of polyphenolic extracts from flowers, in vitro callus and cell suspension cultures of Crataegus monogyna." Pharmazie 52(1): 60-4.
- Reilly, C. M., P. Zamorano, V. S. Stopper and T. M. Mills (1997). "Androgenic regulation of NO availability in rat penile erection [see comments]." J Androl 18(2): 110-5.
- Rogers, K. L., I. D. Grice and L. R. Griffiths (2000). "Inhibition of platelet aggregation and 5-HT release by extracts of Australian plants used traditionally as headache treatments." Eur J Pharm Sci 9(4): 355-63.
- Romics, I., H. Schmitz and D. Frang (1993). "Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year." Int Urol Nephrol 25(6): 565-9.
- Sato, Y., G. J. Christ, H. Horita, H. Adachi, N. Suzuki and T. Tsukamoto (1999). "The effects of alterations in nitric oxide levels in the paraventricular nucleus on copulatory behavior and reflexive erections in male rats." J Urol 162(6): 2182-5.
- Shimada, H., V. E. Tyler and J. L. McLaughlin (1997). "Biologically active acylglycerides from the berries of saw-palmetto (Serenoa repens)." J Nat Prod 60(4): 417-8.
- Sultan, C., A. Terraza, C. Devillier, E. Carilla, M. Briley, C. Loire and B. Descomps (1984). "Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts." J Steroid Biochem 20(1): 515-9.
- Tarayre, J. P., A. Delhon, H. Lauressergues, A. Stenger, M. Barbara, M. Bru, G. Villanova, V. Caillol and M. Aliaga (1983). "[Anti-edematous action of a hexane extract of the stone fruit of Serenoa repens Bartr.]." Ann Pharm Fr 41(6): 559-70.
- Taskov, M. (1977). "On the coronary and cardiotonic action of crataemon." Acta Physiol Pharmacol Bulg 3(4): 53-7.
- Teixeira, C. E., R. A. Moreno, U. Ferreira, N. Rodrigues Netto, Jr., A. Fregonesi, E. Antunes and G. De Nucci (1998). "Pharmacological characterization of kinin-induced relaxation of human corpus cavernosum [see comments]." Br J Urol 81(3): 432-6.
- Vahlensieck, W., Jr., P. G. Fabricius and U. Hell (1996). "[Drug therapy of benign prostatic hyperplasia]." Fortschr Med 114(31): 407-11.
- Vahlensieck, W., Jr., A. Volp, W. Lubos and M. Kuntze (1993). "[Benign prostatic hyperplasia--treatment with sabal fruit extract. A treatment study of 1,334 patients]." Fortschr Med 111(18): 323-6.
- Van Coppenolle, F., X. Le Bourhis, F. Carpentier, G. Delaby, H. Cousse, J. P. Raynaud, J. P. Dupouy and N. Prevarskaya (2000). "Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride." Prostate 43(1): 49-58.
- Weisser, H., S. Tunn, B. Behnke and M. Krieg (1996). "Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia." Prostate 28(5): 300-6.
- Yablonsky, F., V. Nicolas, J. P. Riffaud and F. Bellamy (1997). "Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts [published erratum appears in J Urol 1997 Sep;158(3 Pt 1):889]." J Urol 157(6): 2381-7.
- Yildirim, S., S. Ayan, Y. Sarioglu, Y. Gultekin and S. Uma (2000). "Does diabetes mellitus affect the progress of tolerance to isosorbide dinitrate (ISDN) in corporal tissue?" Nitric Oxide 4(1): 29-34.
Double-Blind Placebo-Controlled Trials Conducted on Ingredients Found In ViriLife and Veromax
- Barlet, A., J. Albrecht, A. Aubert, M. Fischer, F. Grof, H. G. Grothuesmann, J. C. Masson, E. Mazeman, R. Mermon, H. Reichelt and et al. (1990). "[Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study]." Wien Klin Wochenschr 102(22): 667-73.
- Boyle, P., C. Robertson, F. Lowe and C. Roehrborn (2000). "Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia." Urology 55(4): 533-9.
- Bracher, F. (1997). "[Phytotherapy of benign prostatic hyperplasia]." Urologe A 36(1): 10-7.
- Breza, J., O. Dzurny, A. Borowka, T. Hanus, R. Petrik, G. Blane and H. Chadha-Boreham (1998). "Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe." Curr Med Res Opin 14(3): 127-39.
- Carbin, B. E., B. Larsson and O. Lindahl (1990). "Treatment of benign prostatic hyperplasia with phytosterols." Br J Urol 66(6): 639-41.
- Chen, J., Y. Wollman, T. Chernichovsky, A. Iaina, M. Sofer and H. Matzkin (1999). "Effect of oral administration of high-dose nitric oxide donor L- arginine in men with organic erectile dysfunction: results of a double- blind, randomized, placebo-controlled study." BJU Int 83(3): 269-73.
- Dufour, B., C. Choquenet, M. Revol, G. Faure and R. Jorest (1984). "[Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma]." Ann Urol (Paris) 18(3): 193-5.
- Gerber, G. S. (2000). "Saw palmetto for the treatment of men with lower urinary tract symptoms." J Urol 163(5): 1408-12.
- Klotz, T., M. J. Mathers, M. Braun, W. Bloch and U. Engelmann (1999). "Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study." Urol Int 63(4): 220-3.
- Marks, L. S., A. W. Partin, J. I. Epstein, V. E. Tyler, I. Simon, M. L. Macairan, T. L. Chan, F. J. Dorey, J. B. Garris, R. W. Veltri, P. B. Santos, K. A. Stonebrook and J. B. deKernion (2000). "Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia." J Urol 163(5): 1451-6.
- McPartland, J. M. and P. L. Pruitt (2000). "Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study [see comments]." J Am Osteopath Assoc 100(2): 89-96.
- Plosker, G. L. and R. N. Brogden (1996). "Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia." Drugs Aging 9(5): 379-95.
- Schilcher, H. (1999). "[Is there a rational therapy for symptomatic treatment of benign prostatic hyperplasia with phytogenic drugs? Illustrated with the example of the prostate agent from Serenoa repens (Sabal fructus)]." Wien Med Wochenschr 149(8-10): 236-40.
- Strauch, G., P. Perles, G. Vergult, M. Gabriel, B. Gibelin, S. Cummings, W. Malbecq and M. P. Malice (1994). "Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers." Eur Urol 26(3): 247-52.
- Tasca, A., M. Barulli, A. Cavazzana, F. Zattoni, W. Artibani and F. Pagano (1985). "[Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo]." Minerva Urol Nefrol 37(1): 87-91.
- Wilt, T., A. Ishani, G. Stark, R. Mac Donald, C. Mulrow and J. Lau (2000). "Serenoa repens for benign prostatic hyperplasia." Cochrane Database Syst Rev 2.
- Wilt, T. J., A. Ishani, G. Stark, R. MacDonald, J. Lau and C. Mulrow (1998). "Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review [published erratum appears in JAMA 1999 Feb 10;281(6):515] [see comments]." Jama 280(18): 1604-9.
|
|
|
|
|
Back
